Approvals· July 3, 2026 · 17 min read
Lynavoy (linerixibat) FDA approval: first IBAT inhibitor for PBC pruritus
By Ran Chen#FDA Approval#GI and Liver#Rare Disease
Topic
Rare Disease
Rare-disease commercialization, orphan status, access barriers, evidence uncertainty, and launch watchlists.
Approvals· July 3, 2026 · 17 min read
Yuviwel (navepegritide) FDA approval and once-weekly achondroplasia access
Biosimilars· June 29, 2026 · 18 min read
Soliris Biosimilar Cliff: NMOSD Exclusivity Expiry and Payer Step Edits
By Ran Chen#Biosimilars#Interchangeability#Payer Policy
Pricing & Access· May 31, 2026 · 12 min read
Renewal denial after stable disease: documenting continued benefit
Pricing & Access· May 31, 2026 · 10 min read
Split-fill specialty pharmacy programs and access friction
Approvals· May 28, 2026 · 7 min read
Decnupaz coverage guide: pivekimab sunirine access in BPDCN
Pricing & Access· May 27, 2026 · 12 min read
Trikafta and Alyftrek CFTR modulator access guide
Pricing & Access· May 27, 2026 · 12 min read
Tysabri and Tyruko natalizumab biosimilar access guide
Pricing & Access· May 27, 2026 · 15 min read
Vyvgart vs Vyvgart Hytrulo access guide
Pipeline· May 22, 2026 · 13 min read